Table 2.
Potential drugs targeting CSC surface marker in clinical trials.
| Drug | Mechanism of action | Condition or disease | Phase | References |
|---|---|---|---|---|
| P5 | Anti-CD49e/CD29 (integrin α5β1) | Non-small cell lung cancer (NSCLC) | III | (32) |
| ALM-201 | Microtubule inhibitors (binds CD44) | Advanced ovarian cancer and other solid tumors | I | (33) |
| RO-5429083 | Anti-CD44 | Acute myeloid leukemia | I | (34) |
| RG-7356 | Anti-CD44 | Acute myeloid leukemia | I | (35) |
| AMC-303 | CD44 Antigen Exon 6 (CD44v6) inhibitors | Advanced or metastatic malignant solid tumors of epithelial origin | I/II | (36) |
| CX-2009 | Tubulin polymerization inhibitors Anti-ALCAM (CD166) |
Solid tumors | I/II | (37) |
| Chrysin | ABCG2 inhibitors | Chronic lymphocytic leukemia (CLL) | II | (38) |